Pack of 10 vials5 in stockSave 22%Retatrutide 15 mg
Tri-agonist GLP-1 / GIP / glucagon research peptide
Retatrutide tri-agonist research peptide, Australian-shipped. Lab-verified ≥99% purity.
Research Use Only. This compound is sold strictly for in-vitro research and laboratory purposes and is not intended for human consumption or therapeutic use. By purchasing you confirm you are a qualified researcher and agree to our full disclaimer.
Only 5 packs left
Triple-receptor agonist research peptide studied for combined effects on GLP-1, GIP, and glucagon signalling pathways in metabolic research applications.
Retatrutide is a synthetic tri-agonist research peptide that activates the GLP-1, GIP, and glucagon receptors simultaneously. It is part of a new generation of incretin-receptor research compounds developed to study combined activation of multiple metabolic pathways. Quantum Labs supplies Retatrutide as a lyophilised powder for Australian research applications.
Retatrutide is studied alongside other incretin-receptor agonists — semaglutide (single-agonist GLP-1) and tirzepatide (dual-agonist GLP-1/GIP) — in pre-clinical and clinical research literature. The tri-agonist mechanism is the distinguishing feature that places it in its own research category. Material is HPLC-verified to ≥99% purity and ships from Australian stock; supplied for laboratory research use only.
Mechanism
Studied for simultaneous agonism of GLP-1, GIP, and glucagon receptors. Research associated with metabolic rate, satiety, and energy expenditure markers in study populations.
HPLC verified against a ≥99% purity specification. Independently tested by accredited third-party laboratories.
Retatrutide — frequently asked questions
What is Retatrutide?
Retatrutide is a synthetic tri-agonist research peptide that simultaneously activates the GLP-1, GIP, and glucagon receptors. It is a newer-generation incretin-receptor research compound.
Is Retatrutide legal in Australia?
Retatrutide is not an approved therapeutic in Australia and remains available for research and laboratory use when supplied without therapeutic representation. Quantum Labs supplies Retatrutide for research use only — it is not a substitute for prescription weight-loss medication.
What is the difference between Retatrutide and Tirzepatide?
Tirzepatide is a dual-agonist activating GLP-1 and GIP receptors. Retatrutide is a tri-agonist activating GLP-1, GIP, and glucagon receptors. The added glucagon-receptor activity is the distinguishing pharmacological feature of Retatrutide.
What is the difference between Retatrutide and Mounjaro?
Mounjaro is the brand name for the approved prescription medicine tirzepatide. Retatrutide is a separate research peptide with an additional glucagon-receptor agonism. They are different molecules studied in parallel research literature. Quantum Labs does not supply prescription medicines.
What is the typical Retatrutide research dosage?
Published clinical research has used Retatrutide doses across a wide titration range. Research-protocol dosing varies by model. Human therapeutic dosing is not established. Quantum Labs supplies this compound for laboratory and pre-clinical research use only. It is not represented for human therapeutic use, and questions about clinical dosing, treatment effects, or personal use should be directed to a qualified medical practitioner.
Guides related to Retatrutide
Researchers also explore
Pack of 10 vialsSave 22%MOTS-c
Lyophilised powder10 mg · 2 strengths
Mitochondrial-derived metabolic peptide
In 2 stacks
Pack of 10 vialsSave 16%5-Amino-1MQ
Lyophilised powder50 mg · 3 strengths
NNMT inhibitor research compound
Pack of 10 vialsSave 15%L-Carnitine
Sterile solution10 ml × 600 mg/ml
Mitochondrial fatty-acid transporter
In 1 stack